表紙:遺伝子合成の世界市場:成長、動向、予測(2020~2025年)
市場調査レポート
商品コード
824084

遺伝子合成の世界市場:成長、動向、予測(2020~2025年)

Gene Synthesis Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 110 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
遺伝子合成の世界市場:成長、動向、予測(2020~2025年)
出版日: 2020年06月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 110 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の遺伝子合成市場は、2024年にかけてCAGR17.0%で拡大すると予測されています。この成長を支えるのは、ゲノミクスや次世代シーケンシングの分野における研究開発の拡大、ゲノミクスに対する政府の資金援助、個別化医療に対する需要の拡大などです。

当レポートでは、世界の遺伝子合成市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場動向

  • 市場概要
  • 市場促進因子
    • ゲノミクスや次世代シーケンシングの分野における研究開発の拡大
    • ゲノミクスに対する政府の資金援助
    • 個別化医療に対する需要の拡大
  • 市場阻害因子
    • 熟練した専門家の不足
    • コストの高さと技術の複雑さ
  • ポーターズファイブフォース分析

第5章 市場セグメンテーション

  • 手法別
    • オリゴヌクレオチド合成
    • 遺伝子アセンブリ
  • エンドユーザー別
    • 学術研究機関
    • バイオ医薬品メーカー
    • CRO
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合動向

  • 企業プロファイル
    • ATUM (DNA2.0 Inc.)
    • Bio Basic Inc.
    • Beijing SBS Genetech Co. Ltd
    • Eurofins Genomics
    • Genewiz Inc.
    • Genscript Biotech Corp.
    • Merck KGaA
    • OriGene Technologies Inc.
    • Thermo Fisher Scientific Inc. (GeneArt)

第7章 市場の機会と将来動向

目次
Product Code: 64485

Factors that are responsible for the growth of Gene Synthesis market include increasing R&D in the field of genomics and next-generation sequencing, increased government funding toward genomics, and increasing demand for personalized medicine. As personalized medicine aims to provide tailor-made therapies to individual patients, depending on the molecular basis of disease, it has become popular over recent years. Healthcare technology, genomics, connected devices, big data analytics, and artificial intelligence are generating vast amounts of health data and insights. This is enabling healthcare providers to offer better and faster diagnoses, and make more informed treatment decisions. Factors, such as the aging global population and rising prevalence of chronic diseases, are putting unrelenting pressure on the capacity and financial viability of the healthcare systems across the world. Personalized medicine holds the promise of providing better patient care and a high safety margin, while lowering the total healthcare costs. In addition, gene synthesis is also finding its applications in the molecular diagnosis of infectious and genetic diseases. Genetic tests, which can detect genetic variations and predict how a person is likely to respond to certain drugs, are becoming commercially available.

Therefore, increasing focus on personalized medicine and other factors, such as patient-centered approach, are driving the growth of the gene synthesis market.

Key Market Trends

PCR-mediated Assembly is Expected to Grow Rapidly in the Gene Assembly Segment

In the gene synthesis process, the chemical synthesis is typically used to create oligonucleotides of up to 120-150 nucleotide (nt) in length. Therefore, generally, gene assembly techniques are utilized to connect small oligonucleotides with each other, to synthesize the gene of the required length. Over the past three decades, a number of methods have been developed to assemble relatively short synthetic oligonucleotides into longer gene sequences. And the PCR-mediated assembly represents one of the most prominent approaches to mediate assembly of the desired DNA sequence. Pertaining to the broad applications of PCR, such as in molecular diagnostics, forensics, and epidemiology studies, the demand and acceptance of PCR technologies are high, which, in turn, acts as a favorable factor for the development and adoption of PCR-mediated assembly methodologies, by academia and research institutes alike.

North America Dominates the Market and is Expected to do Same during the Forecast Period

Currently, North America dominates the market for gene synthesis, and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. The increasing prevalence of genetic and chronic disorders, such as cancer, aging population, increasing demand for targeted and personalized medicine, and favorable government initiatives are the primary factors responsible for the large market.

Competitive Landscape

The gene synthesis market is moderately competitive and consists of several major players. In terms of the market share, few of the major players currently dominate the market. Owing to the increasing number of diseases and rising drug discovery processes, few other smaller players are expected to enter the market. Some of the major players of the market are Merck KGaA, Genscript Biotech Corp., Genewiz Inc., Eurofins Genomics, and Bio Basic Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing R&D in the Field of Genomics and Next Generation Sequencing
    • 4.2.2 Increased Government Funding toward Genomics
    • 4.2.3 Increasing Demand for Personalized Medicine
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Professionals
    • 4.3.2 High Cost and Complexity of Techniques
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Method
    • 5.1.1 Oligonucleotide Synthesis
      • 5.1.1.1 Solid Phase Phosphoramidite Synthesis
      • 5.1.1.2 Microchip-based Oligonucleotide Synthesis
    • 5.1.2 Gene Assembly
      • 5.1.2.1 Ligation-mediated Assembly
      • 5.1.2.2 PCR-mediated Assembly
  • 5.2 By End User
    • 5.2.1 Academic and Research Institutes
    • 5.2.2 Biopharmaceutical Companies
    • 5.2.3 Contract Research Organizations
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ATUM (DNA2.0 Inc.)
    • 6.1.2 Bio Basic Inc.
    • 6.1.3 Beijing SBS Genetech Co. Ltd
    • 6.1.4 Eurofins Genomics
    • 6.1.5 Genewiz Inc.
    • 6.1.6 Genscript Biotech Corp.
    • 6.1.7 Merck KGaA
    • 6.1.8 OriGene Technologies Inc.
    • 6.1.9 Thermo Fisher Scientific Inc. (GeneArt)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS